Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission filings for Electromed, Inc. (NYSE American: ELMD), a Minnesota-based medical device company that develops, manufactures, and sells airway clearance therapy products such as the SmartVest® Airway Clearance System. These regulatory documents provide detailed insight into Electromed’s financial condition, governance, and material corporate events.
Through periodic reports like the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, Electromed discloses information on its revenues from direct homecare and non-homecare markets, gross profit, operating expenses, research and development, and net income. These filings also describe risk factors related to reimbursement, regulatory compliance, competition, component supply, and other aspects of operating in the medical device industry.
Current Reports on Form 8-K document specific events, such as the announcement of quarterly and annual financial results, updates to investor presentations, approval of share repurchase authorizations, and the entry into a Credit Agreement with BMO Bank N.A. that provides a senior secured revolving credit facility. Other 8-K filings cover shareholder meeting results, including director elections, auditor ratification, and advisory votes on executive compensation.
The Definitive Proxy Statement on Form DEF 14A offers additional detail on corporate governance, board composition, executive and director compensation, equity compensation plans, and the procedures for the annual meeting of shareholders, which Electromed has conducted as a virtual meeting via webcast.
On Stock Titan, Electromed’s SEC filings are available with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as revenue drivers, capital allocation decisions, credit facility terms, and governance matters. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, DEF 14A, and related filings, as well as any insider transaction reports on Form 4, are accessible with clear explanations of their significance for ELMD shareholders and analysts.
Electromed, Inc. (ELMD) reported the results of its annual shareholder meeting held on November 14, 2025. Shareholders elected all nominated directors to the Board, with each nominee receiving substantially more votes "for" than "withheld." Other management proposals also received strong support, including the advisory vote approving executive compensation. Shareholders additionally voted on how often they want an advisory vote on executive pay, and the Board determined, based on these results, to continue including this vote in the proxy materials on an annual basis. These outcomes keep the company’s governance structure and executive pay practices largely unchanged.
Electromed, Inc. (ELMD) reported stronger Q1 FY2026 results. Net revenues rose 15.1% to $16,887,000, led by homecare ($14,889,000), hospital ($1,047,000), and homecare distributors ($829,000). Gross profit was $13,197,000 at 78.1% of revenue. Operating income increased to $2,670,000 and net income grew 44.9% to $2,136,000, with diluted EPS of $0.25.
SG&A was $10,286,000, reflecting investments in sales, travel, and marketing; R&D was $241,000. Cash and cash equivalents were $14,113,000, and total shareholders’ equity reached $44,745,000. Operating cash flow was $169,000 after seasonal compensation payouts and inventory build; capital expenditures were $252,000. The company has a $2,500,000 revolving credit facility with no borrowings outstanding.
Capital returns: A stock repurchase authorization of up to $10,000,000 was approved on September 9, 2025; during the quarter, 40,848 shares were repurchased for $1,003,000 at an average of $24.57. Shares outstanding were 8,340,538 as of November 5, 2025. Management cites a working capital position of approximately $35,800,000 and states liquidity is sufficient for the next twelve months.
Electromed, Inc. (ELMD) furnished an 8-K announcing it issued a press release with financial results for the first quarter ended September 30, 2025, and updated its investor presentation. The press release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2.
The company noted that the information, including Exhibits 99.1 and 99.2, is being furnished and not filed under the Exchange Act, and will not be incorporated by reference into a Securities Act registration statement except as specifically referenced.
Electromed, Inc. is asking shareholders to vote at a fully virtual annual meeting on November 14, 2025. Holders of its 8,376,147 outstanding common shares as of September 17, 2025 can attend and vote online via webcast.
Shareholders will elect eight directors, ratify RSM US LLP as auditor for the year ending June 30, 2026, approve on an advisory basis executive compensation, and choose how often future say‑on‑pay votes are held, with the Board recommending annual votes. The Board recommends voting for all director nominees and for Proposals 2 and 3.
The proxy details compensation for CEO James Cunniff and CFO Bradley Nagel. In fiscal 2025, Cunniff’s total reported pay was $1,486,329, including a $519,231 salary and a $405,600 bonus, while Nagel received $756,674, including a $323,281 salary and a $202,800 bonus after a 156% payout under the 2025 bonus plan. Equity grants include time‑vested restricted stock and options. The filing also shows net income rising to $7,537,000 in 2025 and an increase in total shareholder return since 2023, and outlines board independence, committee structure, equity plans, and related‑party transaction oversight.
Andrew Summers, a director of Electromed, Inc. (ELMD), reported multiple open-market sales of company common stock on September 10 and 11, 2025. The Form 4 shows sales of 39,378, 16,203, 6,576, 404 and 3,153 shares at weighted average prices between $23.6791 and $26.6246, with sale price ranges disclosed for each lot. Some holdings are reported as indirectly owned by investment vehicles (SVP Deal Fund I LP and Summers Value Fund LP), and the filing disclaims direct beneficial ownership except to the extent of pecuniary interest. One reported sale of 3,153 shares on 09/11/2025 reduced the reporting person’s indirect holding in a specified vehicle to 0 shares according to the form. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Electromed, Inc. (ELMD) Form 144 reports a proposed sale of 65,714 shares of common stock via BTIG, LLC on the NYSE American with an aggregate market value of $1,554,136.10. The shares were acquired in the open market on 06/01/2021 and paid for in cash. The filing lists 8,349,176 shares outstanding for the class and shows no securities sold in the past three months. The proposed sale is scheduled for 09/10/2025. The filer affirms there is no undisclosed material adverse information.
Electromed, Inc. announced that its board of directors has approved a new share repurchase authorization. The company may buy back up to $10.0 million of its outstanding common stock over time through open market purchases and privately negotiated transactions. The actual amount and timing of any repurchases will depend on market conditions and other corporate considerations. Details were provided in a press release attached as an exhibit.
Electromed, Inc. (ELMD) Form 4 filed for James L. Cunniff, CEO and President. The filing reports a disposition of 1,291 common shares on 09/02/2025 at $23.95 per share to satisfy tax withholding related to vested restricted stock, reducing his holdings to 130,751 shares. On the same date he was granted 17,000 restricted shares scheduled to vest in three equal annual installments beginning September 2026, and received an employee stock option for 31,100 shares at a $23.95 exercise price exercisable in three equal annual installments beginning September 2026 and expiring 09/02/2035, leaving 31,100 options outstanding.
Electromed, Inc. (ELMD) reporting person Bradley M. Nagel, CFO, made scheduled equity transactions on 09/02/2025 that increased his overall beneficial stake. He disposed of 562 common shares to satisfy tax withholding from restricted stock vesting at an average price of $23.95, leaving him with 16,538 shares prior to additional acquisitions. He acquired 5,300 restricted shares (no cash price) that vest in three equal annual installments beginning September 2026, and received an employee stock option to buy 9,800 shares at a $23.95 exercise price expiring 09/02/2035, vesting in three equal annual installments from September 2026. After the transactions, his beneficial ownership rose to 21,838 common shares plus 9,800 option shares exercisable in the future.
Electromed, Inc. reported details in its Form 10-K that describe its business, capital structure and selected balance sheet and operating items. The company had 8,349,176 shares issued and outstanding as of June 30, 2025, down from 8,637,883 a year earlier after share repurchase programs that retired 280,017 and 220,899 shares in prior authorizations for total costs of $5,000,000 each and are now exhausted. The company maintains a $2.5 million secured line of credit with interest at prime less 1.0% (prime was 7.50% at June 30, 2025). Operating lease liabilities increased to $198,000 from $87,000 and related right-of-use assets and lease terms are disclosed. As of June 30, 2025, unrecognized compensation expense related to non-vested awards was $1,351,000 expected to be recognized over weighted-average periods near two years. The effective tax rates were 26.7% and 26.8% for fiscal 2025 and 2024. The Audit Committee and Board provide oversight of a cybersecurity risk management program co-led by senior management and third-party providers.